Chimeric Therapeutics (ASX:CHM) Advances Phase 1B AML Trial
Trial Progress
Chimeric Therapeutics (ASX: CHM) has successfully completed the dose escalation phase of its ADVENT-AML Phase 1B clinical trial. Six relapsed or refractory Acute Myeloid Leukemia (AML) patients completed treatment without experiencing dose-limiting toxicities or unexpected safety issues. The trial is now expanding to enrol up to 20 newly diagnosed AML patients who are not candidates for chemotherapy or allogeneic stem cell transplants.
Innovative Approach
This trial is pioneering the use of CORE-NK cell therapy in conjunction with standard AML treatments. It aims to assess the effectiveness of this novel approach in improving outcomes for patients with AML. The study will be conducted at The University of Texas MD Anderson Cancer Center under the guidance of Principal Investigator Abhishek Maiti, MD.
Executive Insights
Dr Rebecca McQualter, CEO of Chimeric Therapeutics, expressed pride in advancing the study, stating, “We are proud to open this phase of the study, where CHM CORE-NKs will be incorporated into standard therapy for newly diagnosed AML patients. This novel combination has the potential to transform first line AML therapy and improve outcomes for cancer patients as this is the first time cell therapy has been evaluated in a first line setting in AML.”
Looking Ahead
Chimeric Therapeutics continues developing a diversified portfolio in cell therapy targeting various areas of oncology disease. The promising results from previous trials further encourage the potential for CORE-NK in standard treatment regimens.
Motley Fool contributor Lauren Surplice has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.